Creating a Better Pathologist
Cart 0

2021, December 13-15: Mesenchymal Tumors: From Head to Toe (and Everything in Between)


December 13-15, 2021 - Palm Springs, California

Available Credits 22.5 CME

Schedule | Faculty | Social Distancing Guidelines


Mesenchymal tumors are inherently diagnostically challenging, but a significant practice gap in their interpretation has developed as new entities and genetic abnormalities have emerged. Diagnostic challenges are associated with distinguishing benign spindle cell proliferations from high grade sarcoma due to histologic and immunohistochemical overlap. In addition to benign and malignant categories, contemporary classification of mesenchymal neoplasms emphasizes lesions with intermediate biologic potential, including those that are locally aggressive or rarely metastasize. There are circumstances in which pathologists can render only descriptive diagnoses without precise classification. New discoveries in molecular genetics have clarified some of these problematic lesions. Furthermore, there are newly described entities that practicing pathologists should be aware of so that tumors are appropriately diagnosed and optimally treated. This course, presented by expert mentors and educators, explores a comprehensive panorama of lesions and anatomic sites.


  • Recognize common and problematic mesenchymal lesions of different anatomic sites
  • Become familiar with recently described diagnostic entities
  • Design a panel of ancillary testing that aids in the diagnosis of mesenchymal tumors
  • Avoid pitfalls caused by erroneous interpretation of immunohistochemical stains
  • Understand the diagnostic criteria for malignancy and for the classification of mesenchymal neoplasms


  • Andre Pinto, MD  
    University of Miami Health System


  • Edi Brogi, MD, PhD
    Memorial Sloan Kettering Cancer Center
  • Darcy A. Kerr, MD
    Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth
  • Gregory Y. Lauwers, MD
    H. Lee Moffitt Cancer Center/University of South Florida
  • Andrew E. Rosenberg, MD
    University of Miami Health System
  • Bruce M. Wenig, MD
    Moffitt Cancer Center


The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 22.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


USCAP records courses at the Interactive Learning Center for future educational purposes. By registering for this course, you consent that your likeness may be used by USCAP.


In the context of the pandemic crisis, USCAP is indefinitely suspending its cancellation policy on all scheduled and upcoming courses until there is a resolution or return to normalcy. However, we encourage you to register (without penalty) for advertised courses (months ahead) in anticipation of return to face-to-face conferences. You can secure your position in advance and cancel, if necessary, with full refund.

The Academy is not responsible for travel expenses incurred as a result of an event cancellation.